Pneumococcal Surface Protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice

Vaccine

Volumn 31, Issue 20, 2013, Pages 2465-2470

  Lima, Fernanda A ^a   Miyaji, Eliane N ^a   Quintilio, Wagner ^a   Raw, Isaias ^a   Ho, Paulo L ^a   Oliveira, Maria Leonor S ^a  

^a INSTITUTO BUTANTAN   (Brazil)

Author keywords

Adjuvants; DTP; Pneumococcal vaccines; PspA

Indexed keywords

DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; PNEUMOCOCCAL SURFACE PROTEIN A; PNEUMOCOCCUS VACCINE; TETANUS ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BORDETELLA PERTUSSIS; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; FEMALE; IMMUNIZATION; MOUSE; NONHUMAN; PERTUSSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; SURVIVAL TIME; TREATMENT OUTCOME; VERO CELL;

ALUM COMPOUNDS; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BORDETELLA PERTUSSIS; CERCOPITHECUS AETHIOPS; DIPHTHERIA TOXIN; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; PERTUSSIS TOXIN; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RESPIRATORY MUCOSA; STREPTOCOCCUS PNEUMONIAE; TETANUS TOXIN; VACCINATION; VERO CELLS;

EID: 84877030241     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.026     Document Type: Article

References (30)

1. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(September (9693)):893-902.
2. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378(December (9807)):1962-1973.
3. Briles D.E., Ades E., Paton J.C., Sampson J.S., Carlone G.M., Huebner R.C., et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 2000, 68(February (2)):796-800.
4. Fukuyama Y., King J.D., Kataoka K., Kobayashi R., Gilbert R.S., Oishi K., et al. Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae. J Immunol 2010, 185(August (3)):1755-1762.
5. Arulanandam B.P., Lynch J.M., Briles D.E., Hollingshead S., Metzger D.W. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 2001, 69(November (11)):6718-6724.
6. Ogunniyi A.D., Grabowicz M., Briles D.E., Cook J., Paton J.C. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 2007, 75(January (1)):350-357.
7. McDaniel L.S., Ralph B.A., McDaniel D.O., Briles D.E. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog 1994, 17(November (5)):323-337.
8. Tart R.C., McDaniel L.S., Ralph B.A., Briles D.E. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis 1996, 173(February (2)):380-386.
9. Hollingshead S.K., Becker R., Briles D.E. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 2000, 68(October (10)):5889-5900.
10. Darrieux M., Moreno A.T., Ferreira D.M., Pimenta F.C., de Andrade A.L., Lopes A.P., et al. Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades. J Med Microbiol 2008, 57(March (Pt 3)):273-278.
11. Moreno A.T., Oliveira M.L., Ferreira D.M., Ho P.L., Darrieux M., Leite L.C., et al. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol 2010, 17(March (3)):439-446.
12. Ferreira D.M., Darrieux M., Oliveira M.L., Leite L.C., Miyaji E.N. Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production. Clin Vaccine Immunol 2008, 15(March (3)):499-505.
13. Oliveira M.L., Miyaji E.N., Ferreira D.M., Moreno A.T., Ferreira P.C., Lima F.A., et al. Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS ONE 2010, 5(5):e10863.
14. Brasil M.S., Guia de Vigilância Epidemiológica 2009, Ministério da Saúde, Brasília.
15. Zorzeto T.Q., Higashi H.G., da Silva M.T., Carniel Ede F., Dias W.O., Ramalho V.D., et al. Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants. Clin Vaccine Immunol 2009, 16(April (4)):544-550.
16. Higashi H.G., Luna E., Precioso A.R., Vilela M., Kubrusly F.S., Dias W.O., et al. Acellular and "low" pertussis vaccines: adverse events and the role of mutations. Rev Inst Med Trop Sao Paulo 2009, 51(May-June (3)):131-134.
17. Lima F.A., Ferreira D.M., Moreno A.T., Ferreira P.C., Palma G.M., Ferreira J.M., et al. Controlled inflammatory responses in lungs is associated with protection elicited by a Pneumococcal Surface Protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice. Clin Vaccine Immunol 2012, 19(September (9)):1382-1392.
18. Dias W.O., Horton D.S., Takahashi C.M., Raw I. A Bordetella pertussis acellular vaccine candidate: antigenic characterization and antibody induction. Braz J Med Biol Res 1994, 27(November (11)):2607-2611.
19. Mazzantini R.P., Miyaji E.N., Dias W.O., Sakauchi D., Nascimento A.L., Raw I., et al. Adjuvant activity of Mycobacterium bovis BCG expressing CRM197 on the immune response induced by BCG expressing tetanus toxin fragment C. Vaccine 2004, 22(January (5-6)):740-746.
20. Nascimento I.P., Dias W.O., Quintilio W., Christ A.P., Moraes J.F., Vancetto M.D., et al. Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge. Microbes Infect Inst Pasteur 2008, 10(February (2)):198-202.
21. Abreu P.A., Miyasato P.A., Vilar M.M., Dias W.O., Ho P.L., Tendler M., et al. Sm14 of Schistosoma mansoni in fusion with tetanus toxin fragment C induces immunoprotection against tetanus and schistosomiasis in mice. Infect Immun 2004, 72(October (10)):5931-5937.
22. Ferreira D.M., Moreno A.T., Cianciarullo A.M., Ho P.L., Oliveira M.L., Miyaji E.N. Comparison of the pulmonary response against lethal and non-lethal intranasal challenges with two different pneumococcal strains. Microb Pathog 2009, 47(September (3)):157-163.
23. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30(January (1)):23-32.
24. Berstad A.K., Oftung F., Korsvold G.E., Haugen I.L., Froholm L.O., Holst J., et al. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. Vaccine 2000, 18(May (22)):2323-2330.
25. Mahon B.P., Ryan M.S., Griffin F., Mills K.H. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect Immun 1996, 64(December (12)):5295-5301.
26. PAHO Immunization newsletter 2007, [2007/12/06; Sect. 1-8].
27. Ulloa-Gutierrez R., Avila-Aguero M.L. Pertussis in Latin America: current situation and future vaccination challenges. Expert Rev Vaccines 2008, 7(December (10)):1569-1580.
28. Dagan R., Goldblatt D., Maleckar J.R., Yaich M., Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun 2004, 72(September (9)):5383-5391.
29. Briles D.E., Hollingshead S.K., King J., Swift A., Braun P.A., Park M.K., et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000, 182(December (6)):1694-1701.
30. Nabors G.S., Braun P.A., Herrmann D.J., Heise M.L., Pyle D.J., Gravenstein S., et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 2000, 18(March (17)):1743-1754.